NCT07010406View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

PHASE1CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

June 6, 2025

Primary Completion Date

August 19, 2025

Study Completion Date

August 19, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

Povetacicept

Injection for Subcutaneous Administration.

Trial Locations (2)

68502

Celerion - Lincoln, Lincoln

85283

Celerion - Tempe, Tempe

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY